Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial - Top-Institutions - MDSpire

Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial

  • By

  • Demet Özcan

  • Patricia Switten Nielsen

  • Jan Alsner

  • Mette Holck Nielsen

  • Else Maae

  • Marie Louise Holm Milo

  • Jens Overgaard

  • Birgitte Vrou Offersen

  • Trine Tramm

  • March 13, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Immuno-Oncology
    • Breast Cancer Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Breast Oncology
    • Tumor Immunology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Immunotherapy
    • Breast Cancer

  • #4

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, MA

    Key Differentiators

    • Cancer Immunology
    • Radiation Oncology
    • Breast Cancer

  • #5

    The University of Texas Southwestern Medical Center
    The University of Texas Southwestern Medical Center

    Dallas, TX

    Key Differentiators

    • Radiation Oncology
    • Immunology
    • Breast Cancer

Original Source(s)

Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial

  • by Demet Özcan, Patricia Switten Nielsen, Jan Alsner, Mette Holck Nielsen, Else Maae, Marie Louise Holm Milo, Jens Overgaard, Birgitte Vrou Offersen, Trine Tramm

  • March 13, 2026

Related Content

Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer

Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45 to 64 Years

Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: a dosimetric comparison